These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 17065015)

  • 1. Complete cytogenetic and molecular response to treatment with imatinib mesylate for philadelphia chromosome positive acute myeloid leukemia with multilineage dysplasia.
    Ueda K; Horiike S; Zen K; Misawa S; Taniwaki M
    Leuk Lymphoma; 2006 Sep; 47(9):1967-9. PubMed ID: 17065015
    [No Abstract]   [Full Text] [Related]  

  • 2. Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation.
    Koca E; Cetiner D; Goker H; Aksu S; Ozcebe OI; Haznedaroglu IC; Turgan C
    Clin Nephrol; 2005 Oct; 64(4):324-6. PubMed ID: 16240908
    [No Abstract]   [Full Text] [Related]  

  • 3. [Disease transformation in imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia patients achieved cytogenetic remissions].
    Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Lu DP
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 37(6):612-5. PubMed ID: 16378113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
    Cojbasić I; Macukanović-Golubović L
    Srp Arh Celok Lek; 2010; 138(5-6):305-8. PubMed ID: 20607973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy.
    Rytting ME; Wierda WG
    Leuk Lymphoma; 2004 Aug; 45(8):1623-6. PubMed ID: 15370215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?
    White DL
    Leuk Lymphoma; 2008 Jun; 49(6):1022-3. PubMed ID: 18452091
    [No Abstract]   [Full Text] [Related]  

  • 7. [Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib].
    Cojbasić I; Macukanović-Golubović L
    Vojnosanit Pregl; 2011 Nov; 68(11):911-6. PubMed ID: 22191306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic myeloid leukemia. Sceptical scientists.
    Druker BJ
    Lancet; 2001 Dec; 358 Suppl():S11. PubMed ID: 11784560
    [No Abstract]   [Full Text] [Related]  

  • 9. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
    Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
    Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate in the treatment of chronic myelogenous leukemia.
    Borthakur G; Cortes JE
    Int J Hematol; 2004 Jun; 79(5):411-9. PubMed ID: 15239390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.
    Aleem A; Siddiqui N
    Leuk Lymphoma; 2005 Jul; 46(7):1097-9. PubMed ID: 16019565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response.
    Usman M; Syed NN; Kakepoto GN; Adil SN; Khurshid M
    J Assoc Physicians India; 2007 Feb; 55():103-7. PubMed ID: 17571738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
    J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate.
    Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib.
    Heartin E; Walkinshaw S; Clark RE
    Leuk Lymphoma; 2004 Jun; 45(6):1307-8. PubMed ID: 15360020
    [No Abstract]   [Full Text] [Related]  

  • 16. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of chronic myeloid leukemia with imatinib in the accelerated stage of the disease].
    Bulum J; Labar B; Mikulić M; Bogdanić V; Sertić D; Nemet D; Krecak-Gverić V; Kovacević J; Serventi-Seiwerth R; Mrsić-Davidović S; Zadro R; Boban D
    Lijec Vjesn; 2003; 125(7-8):176-9. PubMed ID: 14692090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP; Croom KF; Goa KL
    BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy.
    Kantarjian HM; Bueso-Ramos CE; Talpaz M; O'Brien S; Giles F; Rios MB; Shan J; Cortes J
    Leuk Lymphoma; 2005 Jul; 46(7):993-7. PubMed ID: 16019549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
    Kantarjian HM; O'Brien S; Cortes JE; Smith TL; Rios MB; Shan J; Yang Y; Giles FJ; Thomas DA; Faderl S; Garcia-Manero G; Jeha S; Wierda W; Issa JP; Kornblau SM; Keating M; Resta D; Capdeville R; Talpaz M
    Clin Cancer Res; 2002 Jul; 8(7):2167-76. PubMed ID: 12114417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.